Supernus Pharmaceuticals Reports 32% Revenue Growth in Q2 2026, Faces Net Loss

Supernus Pharmaceuticals, Inc. reported significant financial results for the second quarter of 2026, with total revenues reaching $219.1 million, a 32% increase from $165.5 million in the same period last year. The growth was driven by net product sales of $165.7 million, up 5% from $158.0 million, and collaboration revenue from ZURZUVAE, which contributed $35.4 million. For the first half of 2026, total revenues were $426.8 million, a 35% increase compared to $315.3 million in the first half of 2025. However, the company reported a net loss of $58.4 million for the quarter, compared to a profit of $22.5 million in the prior year, primarily due to increased operating expenses and an impairment charge of $54.9 million related to the APOKYN intangible asset.

The company's financial position showed a decrease in total assets to $1.43 billion as of June 30, 2026, down from $1.45 billion at the end of 2025. Current assets increased to $723.5 million, driven by higher cash and cash equivalents of $180.4 million, up from $144.7 million. Total liabilities rose to $396.9 million, with current liabilities increasing to $347.4 million, reflecting higher accrued product returns and rebates. Stockholders' equity decreased to $1.03 billion, down from $1.06 billion, largely due to the net loss incurred during the quarter.

Strategically, Supernus completed the acquisition of Sage Therapeutics in July 2025, which has expanded its product portfolio to include ZURZUVAE, the first FDA-approved oral treatment for postpartum depression. The collaboration with Biogen for ZURZUVAE has been fruitful, with a 53% increase in U.S. sales compared to the previous year. The company also announced a merger agreement with Indivior Pharmaceuticals on August 1, 2026, which will see Supernus become a wholly-owned subsidiary of Indivior, further consolidating its market position.

Operationally, Supernus has seen increased engagement with its products, particularly Qelbree, which reported a 15% increase in sales to $89.2 million in the second quarter. The total number of prescriptions for Qelbree rose by 17%, indicating strong market adoption. The company is also working to secure additional supply for ONAPGO, which has faced manufacturing constraints due to high demand. The total employee headcount has increased as the company expands its operations and product offerings.

Looking ahead, Supernus anticipates continued revenue growth driven by its expanding product portfolio and strategic collaborations. However, the company acknowledges potential challenges, including market pressures and the impact of patent expirations on certain products. The management remains focused on optimizing its capital structure and exploring additional financing opportunities to support ongoing operations and future growth initiatives.